The Pharma Sector is Sitting on a Multibagger Opportunity…

By Sonia Boolchandani

Over the past few months, global markets have been influenced significantly by the U.S. presidential election. The mantra, “When America sneezes, the world catches the cold,” rings true, as the policies of a new administration ripple across global economies. One sector poised to benefit from these shifts is India’s pharmaceutical industry, specifically the Contract Development and Manufacturing Organization (CDMO) segment.

With the U.S. increasingly adopting an anti-China stance under President Trump, the potential for India to gain traction in the pharmaceutical sector, especially CDMO services, has grown. While the world speculated on what the election results would mean for various industries, it’s clear that India stands to benefit, particularly in the pharmaceutical manufacturing space.

Why India Could Win Big in the CDMO Space

The U.S. Biosecure Act, a proposed piece of legislation designed to curb reliance on Chinese pharmaceutical and biotech suppliers, has been at the center of these discussions. The Act aims to bar federal contracts with five major Chinese life sciences companies—WuXi AppTec, WuXi Biologics, BGI Group, MGI, and Complete Genomics—citing national security risks tied to China’s involvement in the global pharmaceutical supply chain.

Legislation like the Biosecure Act typically makes its way through the U.S. Congress by passing in both the House of signed into law by the President. This act cleared a major hurdle when Representatives and the Senate before being it garnered overwhelming bipartisan support in the House in September. However, its path to becoming law faced complications when it was excluded from the 2025 National Defense Authorization Act (NDAA), widely seen as its best vehicle for passage.

Despite this setback, the Act remains a critical piece of legislation in ongoing efforts to restructure global pharmaceutical supply chains. If it fails to advance this year, it may face further delays or opposition as new lawmakers take office and priorities shift. For countries like India, however, the broader trend of reducing reliance on China presents a unique opportunity to step in and capture a larger share of the global pharmaceutical and CDMO markets.

India’s pharmaceutical industry, recognized globally for its generics manufacturing capacity, is stepping up to fill the void left by Chinese manufacturers. India already has a robust infrastructure for drug development, coupled with a large pool of skilled labor and lower manufacturing costs.

 » Read More

Related Articles

Infosys Q3 earnings on January 16:  Here are 4 key things the street is watching out for

While majors in the IT sector like Tata Consultancy Services (TCS) and HCL Tech already having released their fiscal third quarter earnings, another giant in the industry, Infosys is all set to release its Q3 numbers on Thursday (January 16). Brokerage firms and analysts said that the company will post a muted revenue growth on

The economic impact of India’s smart cities and creating a growth corridor for business and innovation

– By Deepak Binyani Imagine a nation where cities are not just centers of population but engines of global innovation, economic powerhouses, and beacons of sustainability. India stands at the threshold of this transformation, driven by the Smart Cities Mission—an initiative that has the potential to reshape our urban future and redefine the trajectory of

Capital Infra Trust InVIT IPO: Check GMP, allotment status, and key details ahead of listing

Capital Infra Trust InVIT, a mainboard issue, opened its three-day subscription window from January 7 to January 9, with a price band set between Rs 99 to Rs 100. The issue, having recently concluded its bidding process, is expected to debut on the Indian bourses, BSE and NSE likely on January 17. The allotment of

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Infosys Q3 earnings on January 16:  Here are 4 key things the street is watching out for

While majors in the IT sector like Tata Consultancy Services (TCS) and HCL Tech already having released their fiscal third quarter earnings, another giant in the industry, Infosys is all set to release its Q3 numbers on Thursday (January 16). Brokerage firms and analysts said that the company will post a muted revenue growth on

The economic impact of India’s smart cities and creating a growth corridor for business and innovation

– By Deepak Binyani Imagine a nation where cities are not just centers of population but engines of global innovation, economic powerhouses, and beacons of sustainability. India stands at the threshold of this transformation, driven by the Smart Cities Mission—an initiative that has the potential to reshape our urban future and redefine the trajectory of

Capital Infra Trust InVIT IPO: Check GMP, allotment status, and key details ahead of listing

Capital Infra Trust InVIT, a mainboard issue, opened its three-day subscription window from January 7 to January 9, with a price band set between Rs 99 to Rs 100. The issue, having recently concluded its bidding process, is expected to debut on the Indian bourses, BSE and NSE likely on January 17. The allotment of

Indian Railway Finance Corporation Share Price Today Live Updates, 15 Jan, 2025: Indian Railway Finance Corporation on the radar

Go to Live UpdatesIndian Railway Finance Corporation Share Price Today Live Updates, 15 Jan, 2025: The Indian Railway Finance Corporation share is in news and the counter closed trade on 14 Jan, 2025 at Rs 135.75. The shares touched intraday high of Rs 136.65 in the last trading session while the intraday low was at

Premier Energies Share Price Today Live Updates, 15 Jan, 2025: Premier Energies on the radar

Go to Live UpdatesPremier Energies Share Price Today Live Updates, 15 Jan, 2025: The Premier Energies share is in news and the counter closed trade on 14 Jan, 2025 at Rs 1122.15. The shares touched an intraday high of Rs 1135.35 in the last trading session while the intraday low was at Rs 1087.75. The